Together, these data suggest DEK/IRAK targeting may in fact activate the NFκB pathway, and highlight unexpected signaling connections between DEK/IRAK1 and NFκB in HNSCC which remain to be defined. This evidence concerns the gene DEK and head and neck squamous cell carcinoma.